Skip to main content
Candel Therapeutics, Inc. logo

Candel Therapeutics, Inc. — Investor Relations & Filings

Ticker · CADL ISIN · US1374041093 US Manufacturing
Open in API
Filings indexed 368 across all filing types
Latest filing 2021-07-12 Regulatory Filings
Country US United States of America
Listing US CADL

About Candel Therapeutics, Inc.

https://www.candeltx.com/

Candel Therapeutics, Inc. is a company developing viral immunotherapies designed to activate a patient's immune system to fight cancer. Its approach utilizes two main platforms based on engineered adenovirus and Herpes Simplex Virus (HSV). These investigational, off-the-shelf therapies are administered directly into tumors to induce immunogenic cell death. This process is intended to stimulate a personalized, systemic, and durable anti-tumor response specific to the individual's cancer. The company aims to create treatments that are both efficacious and well-tolerated for patients across various disease stages.

Recent filings

Filing Released Lang Actions
Regulatory Filings 2021
Regulatory Filings
2021-07-12 English
Regulatory Filings 2021
Regulatory Filings Classification · 95% confidence The document is a detailed letter from Candel Therapeutics, Inc. to the SEC Division of Corporation Finance regarding a confidential treatment request related to their Registration Statement on Form S-1. It discusses the valuation of common stock underlying recent equity issuances, including detailed explanations of valuation methods, stock option grants, and fair market value determinations. The letter references the Registration Statement on Form S-1, which is a filing related to an initial public offering (IPO). The content is focused on valuation and accounting for equity issuances, not the actual registration statement or prospectus itself. The document is a correspondence letter addressing SEC comments and requesting confidential treatment, which is typical of regulatory correspondence filings. It does not contain financial statements or a full report but is a regulatory filing related to the registration process. Therefore, it fits best under Regulatory Filings (RNS), as it is a regulatory correspondence and confidential treatment request letter related to a Form S-1 registration statement.
2021-07-07 English
S-1
Capital/Financing Update Classification · 95% confidence The document is a Form S-1 Registration Statement filed with the U.S. Securities and Exchange Commission (SEC) for Candel Therapeutics, Inc. It is a detailed registration statement under the Securities Act of 1933, used for initial public offerings (IPOs). The text includes extensive information typical of an S-1 filing: company overview, risk factors, use of proceeds, management discussion, executive compensation, principal stockholders, underwriting details, and financial statements. This is not an annual or quarterly report, nor an earnings release or other types of filings. It is a capital markets filing related to the company's IPO process, which fits the category of Capital/Financing Update (CAP). The document is lengthy (15,000 characters) and contains substantive information about the offering and company, not just an announcement or certification. Therefore, the correct classification is CAP with high confidence.
2021-06-25 English
Regulatory Filings 2021
Regulatory Filings
2021-04-09 English
Regulatory Filings 2021
Regulatory Filings Classification · 100% confidence The document is a response letter from a company to the SEC staff regarding comments on a Draft Registration Statement on Form S-1. It addresses SEC comments on disclosures, financials, and other regulatory compliance matters related to the registration statement. The document is not a financial report, earnings release, or management discussion but rather a regulatory correspondence related to a registration filing. It does not contain financial statements or substantive financial data but is a regulatory filing responding to SEC comments. Therefore, it fits best under Regulatory Filings (RNS).
2021-03-30 English
Capital/Financing Update 2021
Capital/Financing Update Classification · 100% confidence The document is a Form S-1 Registration Statement filed confidentially with the SEC by Candel Therapeutics, Inc. It is a preliminary prospectus for an initial public offering (IPO) of common stock. The text includes detailed information typical of an IPO prospectus such as risk factors, use of proceeds, management discussion and analysis, executive compensation, principal stockholders, underwriting details, and legal matters. It is not a financial report like an annual or quarterly report, nor is it an earnings release or a regulatory filing of a different nature. The document is a registration statement for securities offering, which falls under Capital/Financing Update filings as it relates to fundraising and capital raising activities.
2021-03-30 English

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.